KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Efficacy and safety of a China-developed live attenuated herpes zoster vaccine in Chinese healthy adults aged 40 years and older: a multicentre, randomized, double-blind, placebo-controlled, phase 3 clinical trial.

Shenyu Wang, Pengfei Jin, Yaru Quan, Huakun Lv, Hongxing Pan, Xiaosong Hu, Qi Liang, Yingping Chen, Mingwei Wei, Qiang Lu, Yidi Wang, Zhenzhen Liang, Jian Fu, Na Xu, Zhiping Chen

Clin Microbiol Infect 32(1) 128-136

PMID40962113
PMCID-
DOI10.1016/j.cmi.2025.09.009
发表日期2025-09-17
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

OBJECTIVES: To evaluate the efficacy and safety of a live-attenuated gelatin-free herpes zoster (HZ) vaccine in adults ≥40 years. METHODS: In a multicentre, randomized, double-blind, placebo-controlled phase 3 trial (2020-2021, Zhejiang and Jiangsu provinces), HZ-naïve adults stratified by age (40-49, 50-59, 60-69, and ≥70 years) were randomized 1:1 to receive a single dose of the HZ vaccine (≥4.3 lg PFU) or placebo and followed for 13 months. The primary endpoint was the incidence of HZ; safety outcomes included adverse events (AEs) and serious AEs. RESULTS: The trial included 25 000 participants. HZ incidence was 5.3 versus 12.6/1000 person-years in the vaccine and placebo groups, respectively, resulting in a vaccine efficacy of 57.6% (95% CI: 43.1-68.7%) overall. Per age stratum, vaccine efficacy was 37.4% (95%CI: -117.0% to 83.9%), 62.7% (39.6-77.7%), 64.4% (42.5-78.7%), and 18.63% (-80.4% to 64.0%) in the 40-49, 50-59, 60-69, and ≥70 age groups, respectively. Few postherpetic neuralgia cases occurred (n = 13), limiting vaccine efficacy assessment. Solicited AEs were mild/moderate (13.8% [1719/12 491] vaccine vs. 5.1% [634/12 499] placebo), with no vaccine-related serious AEs. Grade 3 reactions, such as fever, were rare (0.06%, [7/12 491]), and AE rates declined with age (22.0% [219/995] in 40-49 vs. 9.1% [136/1499] in ≥70). DISCUSSION: China's gelatin-free HZ vaccine is safe and moderately effective, particularly in adults aged 50-69 years, with an age-dependent safety profile.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。